On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.

The proceeds from this financing will fund Immutrin’s lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis.

The Wilson Sonsini team that advised Frazier Life Sciences on patent matters related to the transaction included Laurie McNamara, Sean Reed, and Michael Hostetler.

For more information, please see Immutrin’s news release. Additional coverage can be found on BioPharma Dive.